Vogenx (NASDAQ:VOGX) Coverage Initiated at JonesTrading

Equities research analysts at JonesTrading assumed coverage on shares of Vogenx (NASDAQ:VOGX) in a research report issued on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $55.00 price target on the stock. JonesTrading’s price target points to a potential upside of 64.13% from the company’s previous close.

Separately, Wall Street Zen raised shares of Vogenx to a “hold” rating in a research note on Saturday, August 22nd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $55.00.

Vogenx Stock Performance

NASDAQ VOGX traded down $0.49 on Tuesday, hitting $33.51. The company’s stock had a trading volume of 293,573 shares, compared to its average volume of 240,271. Vogenx has a 1-year low of $12.95 and a 1-year high of $35.50.

About Vogenx

Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.